# US 2009/0269339 A1 · Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269339 A1
- Document ID: US20090269339A1
- Status: Published application
- Kind: A1
- Application number: 12/431,057
- Filed: 2009-04-28
- Published: 2009-10-29
- Earliest claimed: 2008-04-29
- Assignees: Genentech, Inc.
- Inventors: Ariella Kelman; Benjamin L. Trzaskoma
- Web page: https://patentgrep.com/patent/US20090269339A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 39/092: {Streptococcus}
- A61K 39/39541: {against normal tissues, cells}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/2887: {against CD20}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/72: Increased effector function due to an Fc-modification
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides clinical data evaluating the efficacy of responses to immunizations in rheumatoid arthritis (RA) patients treated with a CD20 antibody.

## Claims

### Claim 1

A method of treating a human rheumatoid arthritis (RA) patient comprising administering to the patient: (a) a CD20 antibody in an amount effective to treat the RA, and (b) a protein vaccine in an amount effective to mount a memory immune response to the protein vaccine.

### Claim 2 (depends on 1)

The method of claim 1 wherein the protein vaccine is a tetanus toxoid vaccine.

### Claim 3 (depends on 1)

The method of claim 1 wherein the protein vaccine is administered to the patient following administration of the CD20 antibody.

### Claim 4 (depends on 3)

The method of claim 3 wherein the protein vaccine is administered about six months after administration of the CD20 antibody.

### Claim 5 (depends on 1)

The method of claim 1 wherein the patient has a 4-fold increase in anti-protein titer following administration of the protein vaccine.

### Claim 6 (depends on 2)

The method of claim 2 wherein the patient has a 4-fold increase in anti-tetanus titer following administration of the tetanus toxoid vaccine.

### Claim 7 (depends on 1)

The method of claim 1 further comprising administering methotrexate to the patient in an amount effective to treat the RA.

### Claim 8 (depends on 7)

The method of claim 7 wherein the memory response to the vaccine is about the same as that mounted in a patient treated with methotrexate without the CD20 antibody.

### Claim 9 (depends on 1)

The method of claim 1 further comprising eliciting a delayed-type hypersensitivity (DTH) response by administering to the patient an antigen which results in a T-cell mediated response in an amount effective to generate the DTH response.

### Claim 10 (depends on 9)

The method of claim 9 wherein the antigen which generates the DTH response is C. Albicans.

### Claim 11 (depends on 1)

The method of claim 1 further comprising administering a polysaccharide vaccine to the patient in an amount effective to mount an immune response to the polysaccharide vaccine.

### Claim 12 (depends on 11)

The method of claim 11 wherein the polysaccharide vaccine is pneumococcal polysaccharide vaccine.

### Claim 13 (depends on 1)

The method of claim 1 further comprising administering a neoantigen vaccine to the patient in an amount effective to mount a primary humoral immune response to the neoantigen vaccine.

### Claim 14 (depends on 13)

The method of claim 13 wherein the neoantigen is Keyhole Limpet Hemocyanin (KLH).

### Claim 15 (depends on 1)

The method of claim 1 wherein the CD20 antibody is selected from the group consisting of a chimeric, humanized, and human CD20 antibody.

### Claim 16 (depends on 1)

The method of claim 1 wherein the CD20 antibody is rituximab.

### Claim 17 (depends on 1)

The method of claim 1 wherein the CD20 antibody is humanized 2H7.

### Claim 18 (depends on 1)

The method of claim 1 wherein the CD20 antibody is ofatumumab.

### Claim 19 (depends on 1)

The method of claim 1 wherein the CD20 antibody is veltuzumab.

### Claim 20 (depends on 1)

The method of claim 1 wherein the CD20 antibody is TRU-015.

### Claim 21 (depends on 1)

The method of claim 1 wherein the CD20 antibody is GA 101.

### Claim 22 (depends on 1)

The method of claim 1 wherein the CD20 antibody is AME-133v.

### Claim 23

A method of mounting a 4-fold increase in anti-protein titer in a human rheumatoid arthritis (RA) patient following vaccination with a protein vaccine, comprising administering the protein vaccine to a RA patient who has been treated with a CD20 antibody, and measuring the 4-fold increase in anti-protein titer in the patient.

### Claim 24

A method of treating human patients having rheumatoid arthritis (RA) comprising treating a first group of the RA patients with a CD20 antibody, methotrexate, and a protein vaccine, and treating a second group of the RA patients with methotrexate and the protein vaccine but not the CD20 antibody, and determining that memory immune responses raised by the first and second groups of patients are about the same.

### Claim 25 (depends on 24)

The method of claim 24 wherein the protein vaccine is tetanus toxoid and the immune response is 4-fold increase in anti-tetanus titer following vaccination with the tetanus toxoid vaccine.

### Claim 26 (depends on 24)

The method of claim 24 wherein the first group of patients includes at least 50 patients.

### Claim 27

A method for advertising a CD20 antibody comprising promoting the use of the CD20 antibody for treating a human rheumatoid arthritis (RA) patient, wherein the RA patient is able to mount an effective memory immune response to a protein vaccine administered following administration of the CD20 antibody.

### Claim 28 (depends on 27)

The method of claim 27 wherein the protein vaccine is a tetanus toxoid vaccine.

### Claim 29 (depends on 27)

The method of claim 27 wherein the effective memory immune response is selected from the group consisting of a 2-fold rise in anti-tetanus titer and 4-fold rise in anti-tetanus titer.

### Claim 30 (depends on 27)

The method of claim 27 wherein the patient is further able to mount an immune response to a polysaccharide vaccine or to a neoantigen vaccine.

### Claim 31 (depends on 30)

The method of claim 30 wherein the polysaccharide vaccine is pneumococcal polysaccharide vaccine and the neoantigen vaccine is Keyhole Limpet Hemocyanin (KLH).

### Claim 32

A method of providing a pharmaceutical composition for treating a human rheumatoid arthritis (RA) patient, comprising combining a container holding a pharmaceutically acceptable composition comprising a CD20 antibody with a package insert, wherein the package insert promotes the use of the composition to treat a RA patient who is able to mount an effective memory immune response to a protein vaccine administered following administration of the CD20 antibody.
